ALMS NASDAQ
Alumis Inc. Common Stock
1W: -8.4%
1M: -12.9%
3M: -21.7%
YTD: +140.3%
1Y: +283.1%
$21.68
+0.15 (+0.72%)
Weekly Expected Move ±8.5%
$19
$21
$23
$25
$27
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$38.7M
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.7B
52W Range2.76-30.6
Volume1,334,367
Avg Volume1,340,898
Beta-0.29
Dividend—
Analyst Ratings
Company Info
CEOMartin Babler
Employees168
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-22
Websitealumis.com
280 East Grand Avenue
South San Francisco, CA 94080
US
South San Francisco, CA 94080
US
(650) 231-6625
About Alumis Inc. Common Stock
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Latest News
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Foresite Labs, LLC | J-Other | 1,123,337 | — | 2026-04-01 |
| Foresite Labs, LLC | J-Other | 680,486 | — | 2026-04-01 |
| Foresite Labs, LLC | J-Other | 1,123,337 | — | 2026-04-01 |
| Foresite Capital Man | J-Other | 1,123,337 | — | 2026-04-01 |
| Foresite Capital Man | J-Other | 680,486 | — | 2026-04-01 |